UY36651A - Compuestos antiestrogénicos - Google Patents

Compuestos antiestrogénicos

Info

Publication number
UY36651A
UY36651A UY0001036651A UY36651A UY36651A UY 36651 A UY36651 A UY 36651A UY 0001036651 A UY0001036651 A UY 0001036651A UY 36651 A UY36651 A UY 36651A UY 36651 A UY36651 A UY 36651A
Authority
UY
Uruguay
Prior art keywords
compounds
antiestrogenic compounds
disorders
present
antiestrogenic
Prior art date
Application number
UY0001036651A
Other languages
English (en)
Inventor
Cyrus L Harmon
Hodges Gallagher Leslie Carol
Peter J Kushner
Myles David C Us
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY36651A publication Critical patent/UY36651A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

La presente descripción proporciona un compuesto de la fórmula I:o una sal farmacéuticamente aceptable, en donde X, R1-R8, Y1-Y5, m, n, p y q se definen en la presente. Los nuevos compuestos de 2H-cromeno son de utilidad para la modulación de trastornos mediados por estrógeno y otros trastornos, como se describen en la presente. La presente invención también se refiere a composiciones farmacéuticas con contenido de los compuestos y a métodos de uso de los compuestos y las composiciones.
UY0001036651A 2015-04-27 2016-04-25 Compuestos antiestrogénicos UY36651A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562153097P 2015-04-27 2015-04-27

Publications (1)

Publication Number Publication Date
UY36651A true UY36651A (es) 2016-11-30

Family

ID=55863140

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036651A UY36651A (es) 2015-04-27 2016-04-25 Compuestos antiestrogénicos

Country Status (6)

Country Link
US (2) US20160311805A1 (es)
AR (1) AR104415A1 (es)
CA (1) CA2928060A1 (es)
TW (1) TW201710253A (es)
UY (1) UY36651A (es)
WO (1) WO2016174551A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018006121B1 (pt) 2015-10-01 2024-01-23 Olema Pharmaceuticals, Inc COMPOSTOS DE TETRA-HIDRO-1H-PIRIDO[3,4-b]INDOL, COMPOSIÇÕES COMPREENDENDO OS REFERIDOS COMPOSTOS E USOS DOS MESMOS
WO2017100715A1 (en) 2015-12-09 2017-06-15 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulator compounds
WO2017182493A1 (en) 2016-04-20 2017-10-26 Astrazeneca Ab Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer
US10149839B2 (en) 2016-07-25 2018-12-11 Astrazeneca Ab Chemical compounds
UA125824C2 (uk) 2016-10-24 2022-06-15 Астразенека Аб 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ
EA201991622A1 (ru) 2017-01-06 2020-01-23 Г1 Терапьютикс, Инк. Комплексная терапия для лечения рака
WO2018138739A1 (en) 2017-01-27 2018-08-02 Sun Pharma Advanced Research Company Limited Novel antiestrogenic heterocyclic compounds
MA52555A (fr) 2017-01-30 2021-03-17 Astrazeneca Ab Modulateurs du récepteur des oestrogènes
CA3089298A1 (en) * 2018-01-22 2019-07-25 Radius Pharmaceuticals, Inc. Estrogen receptor-modulating compounds
WO2020163637A1 (en) * 2019-02-06 2020-08-13 Oregon Health & Science University Bisphosphonate-linked compounds
US11014915B2 (en) 2019-07-22 2021-05-25 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2586908T3 (es) * 2010-12-24 2016-10-19 Merck Sharp & Dohme B.V. Derivados de azetidina N-sustituidos
MX2015016171A (es) * 2013-06-19 2016-08-08 Seragon Pharmaceuticals Inc Moduladores del receptor de estrogeno de azetidina y usos de los mismos.

Also Published As

Publication number Publication date
CA2928060A1 (en) 2016-10-27
US20170362210A1 (en) 2017-12-21
US20160311805A1 (en) 2016-10-27
WO2016174551A1 (en) 2016-11-03
AR104415A1 (es) 2017-07-19
TW201710253A (zh) 2017-03-16

Similar Documents

Publication Publication Date Title
UY36651A (es) Compuestos antiestrogénicos
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CL2017001017A1 (es) Nuevos compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CL2017001050A1 (es) Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
CR20170564A (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CO7180201A2 (es) Inhibidores de neprilisina
CR20140275A (es) Triazolopiridinas sustituidas
CL2017000820A1 (es) Compuestos de aminopurina sustituida, composiciones de los mismos, y metodos de tratamiento con los mismos
CR20150045A (es) Inhibidores de hepatitis c
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
CU20150021A7 (es) Piridinonas bicíclicas novedosas
CR20160016A (es) Pirazolpiridinas sustituidas
EA201591451A1 (ru) Модуляторы flap
UY34169A (es) ?compuestos heterociclicos microbiocidas,composiciones que los contienen, y métodos para controlar o prevenir la infestación de plantas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221114